The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
BUSINESS
Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
Ono Pharmaceutical reached a settlement with Nobel laureate Tasuku Honjo in their patent royalty battle over Opdivo (nivolumab) on November 12, agreeing to pay out a total of 28 billion yen including a 23-billion-yen donation for young researchers. Prof. Honjo…
To read the full story
Related Article
- Research Foundation Set Up at Kyoto University after Opdivo Settlement
December 14, 2021
- Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
- Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
- Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021
- Ono Chief, Honjo to Face Off in Opdivo Royalty Feud on September 2
August 3, 2021
- Honjo Ups Royalty Claim after Tecentriq Settlement: Opdivo Row
June 14, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Ono, Prof. Honjo Disagree About Validity of Patent Royalty Rate for Opdivo
January 6, 2021
- Ono/BMS Sign Patent License Deal for Tecentriq with Roche
November 10, 2020
- Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
- Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
- Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
- Ono President Confident of Validity of Company’s Argument on Opdivo Royalties
June 19, 2020
- Nobel Laureate Honjo Taking Ono to Court, Demands 22.6 Billion Yen
June 8, 2020
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Ono Offers Its Account of License Fee Row with Nobel Laureate
May 23, 2019
- I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
BUSINESS
- AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh
May 19, 2022
- Sosei, Kallyope Partner in R&D of GPCR Targets for GI Drug Discovery
May 18, 2022
- Ricoh to Venture into mRNA Drug Discovery Support Biz with Elixirgen Buy
May 18, 2022
- Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
- AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…